Testosterone increases serum 1,25-dihydroxyvitamin D and insulin-like growth factor-I in hypogonadal men.
The short-term metabolic effects of testosterone treatment on circulating levels of 1,25-dihydroxyvitamin D and insulin-like growth factor-I (IGF-I) were studied in 13 hypogonadal men. The study group included 11 men with Klinefelter's syndrome, with varying degree of androgen deficiency, and two men with secondary hypogonadism. Pretreatment levels of 1,25-dihydroxyvitamin D, vitamin D-binding protein and IGF-binding protein-I were all within the normal range. The levels of IGF-I were lower than normal in 5/11 of the Klinefelter patients and in one patient with GH-deficiency. Testosterone treatment increased circulating total 1,25-dihydroxyvitamin D significantly from 75 +/- 4 pmol l-1 (mean +/- SEM) to 86 +/- 4 (P less than 0.01) and the free 1,25-dihydroxyvitamin D-index from 1.95 +/- 0.11 to 2.39 +/- 0.12 (P less than 0.01). Serum levels of IGF-I increased from 117 +/- 22 micrograms/l to 143 +/- 23 (P less than 0.01) during androgen treatment. No significant effects on levels of IGF-binding protein-I were seen. It is concluded that androgen therapy increases the availability of 1,25-dihydroxyvitamin D and the level of IGF-I, which may be important links in the action of testosterone.
Hagenfeldt
Y
Y
Department of Clinical Chemistry I, Huddinge University Hospital, Sweden.
Linde
K
K
Sjöberg
H E
HE
Zumkeller
W
W
Arver
S
S
D000293:Adolescent; D002117:Calcitriol / Q000097:blood*; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007713:Klinefelter Syndrome / Q000150:complications; D008297:Male; D008875:Middle Aged; D013739:Testosterone / Q000494:pharmacology*
D013739:Testosterone; D007334:Insulin-Like Growth Factor I; D002117:Calcitriol